Want to commission a custom market research to suit your needs? We are here to help. Let us know.
Gastric and Gastroesophageal Junction Adenocarcinoma - Current and Future Players
GlobalData has released its pharma report, “Gastric and Gastroesophageal Junction Adenocarcinoma - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Gastric and Gastroesophageal Junction Adenocarcinoma (G/GEJAC) Market. The report identifies and analyses the key companies shaping and driving the global G/GEJAC market. The report provides insight into the competitive G/GEJAC landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.
- Investigation of current and future market competition for G/GEJAC
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of G/GEJAC sector through market impact analysis, future market scenario and company analysis
Reasons to buy
- Gain a high level view of the trends shaping and driving G/GEJAC market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global G/GEJAC market landscape? Identify, understand and capitalize
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.2 Related Reports
2.3 Upcoming Related Reports
3 Market Outlook
3.1 Global Markets
3.1.2 Drivers and Barriers - Global Issues
4 Current and Future Players
4.2 Trends in Corporate Strategy
4.3 Company Profiles
4.3.1 Bristol-Myers Squibb
4.3.2 Eli Lilly and Company
4.3.3 Merck & Co.
4.3.5 Taiho Pharmaceutical
4.3.6 Sumitomo Dainippon Pharma
5.4 Forecasting Methodology
5.4.1 Hospitalized MRSA Patients
5.4.2 Percentage of Drug-Treated MRSA Patients
5.4.3 Drugs Included in Each Therapeutic Class
5.4.4 Launch, Label Expansion, and Patent Expiry Dates
5.4.5 General Pricing Assumptions
5.4.6 Individual Drug Assumptions
5.4.7 Generic Erosion
5.4.8 Pricing of Pipeline Agents
5.5 Primary Research - KOLs Interviewed for This Report
5.6 Primary Research - Prescriber Survey
5.7 About the Authors
5.7.1 Author and Therapy Area Director
5.7.4 Global Director of Therapy Analysis and Epidemiology
5.7.5 Global Head of Healthcare
5.8 About GlobalData
1.1 List of Tables
Table 1: Global Sales Forecast ($m) for G/GEJAC, 2014-2024
Table 2: G/GEJAC Market - Drivers and Barriers, 2015
Table 3: Key Companies in the G/GEJAC Market in the 8MM, 2014-2024
Table 4: BMS’ G/GEJAC Portfolio Assessment, 2015
Table 5: Eli Lilly’s G/GEJAC Portfolio Assessment, 2015
Table 6: Merck & Co.’s G/GEJAC Portfolio Assessment, 2015
Table 7: Roche’s G/GEJAC Portfolio Assessment, 2015
Table 8: Taiho’s G/GEJAC Portfolio Assessment, 2015
Table 9: SDP’s G/GEJAC Portfolio Assessment, 2015
Table 10: Key Historical and Projected Launch Dates for MRSA Across the 7MM
Table 11: Key Historical and Projected Label Expansion Dates for MRSA Across the 7MM
Table 12: Key Historical and Projected Patent Expiry Dates for MRSA Across the 7MM
Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Global Sales for G/GEJAC by Region, 2014-2024
Figure 2: Global Sales of Branded Products for G/GEJAC by Company, 2014-2024
Figure 3: Company Portfolio Gap Analysis in G/GEJAC, 2014-2024
Figure 4: Bristol-Myers Squibb SWOT Analysis in G/GEJAC, 2014-2024
Figure 5: Eli Lilly SWOT Analysis in G/GEJAC, 2014-2024
Figure 6: Roche SWOT Analysis in G/GEJAC, 2014-2024
Figure 7: Taiho SWOT Analysis in G/GEJAC, 2014-2024
Figure 8: Sumitomo Dainippon SWOT Analysis in G/GEJAC, 2014-2024
Eli Lilly and Company
Merck & Co.
Sumitomo Dainippon Pharma
Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?
If yes, then please use the form given below and we will get in touch with you immediately.
Kindly use your official email address and contact number to ensure speedy response.